Vanillin, the primary phytochemical studied for its anti-tumor properties, targets proteins such as Transient Receptor Potential Vanilloid Subtype 1 (TRPV1), as well as cytoplasmic peptides like Microtubule Affinity-Regulating Kinase 4 (MARK4), Human Calcium/Calmodulin-Dependent Protein Kinase IV (CAMK4), and Casein Kinase II Subunit (CK2) [140]. The gene discussed is CAMK4; the disease is neoplasm.